Patents by Inventor Mathias Uhlen

Mathias Uhlen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110003854
    Abstract: The present invention provides a new method and means for determining whether a mammalian subject having a breast cancer is likely to benefit from an endocrine treatment. The method comprise the steps of: providing a sample earlier obtained from said subject; evaluating the amount of CRABP2 protein present in at least part of said sample, and determining a sample value corresponding to said amount; comparing the obtained sample value with a reference value; and, if said sample value is higher than said reference value, concluding that the subject is likely to benefit from an endocrine treatment.
    Type: Application
    Filed: December 16, 2008
    Publication date: January 6, 2011
    Inventors: Fredrik Ponten, Mathias Uhlen, Karin Jirstrom
  • Publication number: 20090220975
    Abstract: The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.
    Type: Application
    Filed: June 4, 2007
    Publication date: September 3, 2009
    Applicant: ATLAS ANTIBODIES AB
    Inventors: Mathias Uhlen, Fredrik Ponten
  • Publication number: 20080233660
    Abstract: The invention provides for the labeling of antibodies with a fluorescent label, using a solid support comprising an affinity for an Fc portion of an antibody. Thus, the invention provides a method for labeling an antibody or fragment thereof with a fluorescent label, comprising the steps of immobilizing an antibody on the solid support and covalently coupling a fluorescent label to the immobilized antibody, as well as a kit for performing such method.
    Type: Application
    Filed: March 20, 2008
    Publication date: September 25, 2008
    Applicant: MU Bioteknik AB
    Inventors: Mathias Uhlen, Helene Andersson Svahn, Emma Lundberg
  • Publication number: 20060035265
    Abstract: The present invention relates to a nucleic acid molecule or a polypeptide that is selected from a method that includes cell-free expression of nucleic acid molecules immobilized on a sold support system. The present invention also relates to a molecular library that has a solid support system having a plurality of nucleic acid molecules immobilized thereon.
    Type: Application
    Filed: October 3, 2005
    Publication date: February 16, 2006
    Inventors: Per-Ake Nygren, Mathias Uhlen, Olof Nord
  • Patent number: 6955877
    Abstract: A method for the selection of one or more desired polypeptides includes cell free expression of nucleic acid molecules immobilized on a solid support system to produce polypeptides. The solid support carrying system is for biospecific interaction with at least the desired polypeptide or a molecule attached thereto. The method also includes separation of the solid support carrying both the desired polypeptide and the nucleic acid encoding it. Finally, the method optionally includes recovery of the nucleic acid and/or the desired polypeptide, and molecular libraries for use in these methods.
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: October 18, 2005
    Assignee: Affibody AB
    Inventors: Per-Ake Nygren, Mathias Uhlen, Olof Nord
  • Publication number: 20050100970
    Abstract: Methods of affinity separation wherein the affinity ligand is immobilized proteinaceous ligand wherein one or more of its asparagine (Asn) residues has been modified. Methods of making a stabilized combinatorial protein by a) modification of Asn residues within a protein molecule to increase stability of the protein in alkaline conditions, and b) randomization of the protein molecule to modify its binding characteristics, and combinatorial proteins wherein in a step separate from the randomization step, the stability of the protein in alkaline conditions has been increased by modifying one or more of its Asn residues.
    Type: Application
    Filed: December 1, 2004
    Publication date: May 12, 2005
    Inventors: Mathias Uhlen, Sophia Hober
  • Patent number: 6831161
    Abstract: Methods of affinity separation wherein the affinity ligand is an immobilized proteinaceous ligand wherein one or more of its asparagine (Asn) residues has been modified. Methods of making a stabilized combinatorial protein by a) modification of Asn residues within a protein molecule to increase stability of the protein in alkaline conditions, and b) randomization of a protein molecule to modify its binding characteristics, and combinatorial proteins wherein in a step separate from the randomization step, the stability of the protein in alkaline conditions has been increased by modifying one or more of its Asn residues.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: December 14, 2004
    Assignee: Affibody AB
    Inventors: Mathias Uhlén, Sophia Hober
  • Patent number: 6740734
    Abstract: Novel proteins obtainable by mutagenesis of surface-exposed amino acids of domains of natural bacterial receptors, said proteins being obtained without substantial loss of basic structure and stability of said natural bacterial receptors; proteins which have been selected from a protein library embodying a repertoire of said novel proteins; and methods for the manufacture of artificial bacterial receptor structures.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: May 25, 2004
    Assignee: Biovitrum AB
    Inventors: Björn Nilsson, Per-Åke Nygren, Mathias Uhlén
  • Publication number: 20040005669
    Abstract: The present invention provides a method of producing an insulin C-peptide, which comprises expressing in a host cell a multimeric polypeptide comprising multiple copies of a said insulin C-peptide, and cleaving said expressed polypeptide to release single copies of the insulin C-peptide.
    Type: Application
    Filed: May 6, 2003
    Publication date: January 8, 2004
    Inventors: Stefan Stahl, Mathias Uhlen, Per-Ake Nygren, Per Jonasson
  • Patent number: 6610479
    Abstract: Enzymes or catalytic fragments thereof reversibly inactivated by attachment to an immobilizing moiety which may comprise a magnetic particle are activated by release from the immobilizing moiety. The enzyme or fragment may be in the form of a fusion protein that is attached to the immobilizing moiety via a pair of affinity binding partners such that the enzyme or fragment is reversibly inactivated, and release of the fusion protein from the immobilizing moiety activates the enzyme or fragment. Enzymes include DNA polymerases, DNA ligases, Reverse transcriptases and RNA polymerases. The enzyme or fragment may be thermostable, and the fusion protein can be bound to the immobilizing moiety via a heat-labile linkage. Activation of the reversibly inactivated immobilized enzyme or fragment has particular utility in PCR and analogous nucleic acid amplification techniques.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: August 26, 2003
    Assignee: Dynal AS
    Inventors: Joakim Lundeberg, Mathias Uhlén
  • Patent number: 6602977
    Abstract: The present invention relates to modified polypeptide derivatives of the B domain or Z domain of staphylococcal protein A (SPA). The derivatives contain amino acid substitutions that result in the ability of the B domain or Z domain to interact with at least one domain of a human Factor VIII protein, without substantially disrupting the structure and stability of the B domain or Z domain.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: August 5, 2003
    Assignee: Biovitrum AB
    Inventors: Charlotta Ljungqvist, Karin Nord, Per-Åke Nygren, Mathias Uhlén
  • Patent number: 6558673
    Abstract: A complex of an immunogen and a support molecule, characterized in that the immunogen is coupled covalently to a support molecule, wherein the support molecule is a polypeptide fragment which is able to bind specifically to mammalian serum albumin is disclosed. The invention also relates to the use of such complexes to treat RSV infection, as well as vaccines derived from such complexes.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: May 6, 2003
    Assignee: Pierre Fabre Medicament
    Inventors: Hans Binz, Thien Ngoc Nguyen, Christine Andreoni, Ake Per Nygren, Stefan Stahl, Mathias Uhlen
  • Patent number: 6558924
    Abstract: The present invention provides a method of producing an insulin C-peptide, which comprises expressing in a host cell a multimeric polypeptide comprising multiple copies of the insulin C-peptide, and cleaving the expressed polypeptide to release single copies of the insulin C-peptide. Also provided are nucleic acid molecules, expression vectors and host cells, for use in such a method and the multimeric insulin C-peptide polypeptide expressed and cleaved in such a method.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: May 6, 2003
    Assignee: Creative Peptides Sweden AB
    Inventors: Stefan Stahl, Mathias Uhlen, Per-Ake Nygren, Per Jonasson
  • Patent number: 6534628
    Abstract: Novel proteins obtainable by mutagenesis of surface-exposed amino acids of domains of natural bacterial receptors, said proteins being obtained without substantial loss of basic structure and stability of said natural bacterial receptors; proteins which have been selected from a protein library embodying a repertoire of said novel proteins; and methods for the manufacture of artificial bacterial receptor structures.
    Type: Grant
    Filed: May 21, 1998
    Date of Patent: March 18, 2003
    Assignee: Biovitrum AB
    Inventors: Björn Nilsson, Per-Åke Nygren, Mathias Uhlén
  • Patent number: 6482592
    Abstract: The invention provides a method of improving the binding of a series of consecutive nucleotide bases to a complementary target nucleic acid molecule in a sample, wherein said method comprises at least the step or steps of binding a complementary modular oligonucleotide of at least two parts (modules) including said nucleotide bases to adjacent stretches of said target nucleic acid molecule in said sample, especially methods of detection/isolation, particularly in the isolation of primer extension products and methods in which the modular oligonucleotide is a primer, modular oligonucleotides themselves and their use in methods of the invention.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: November 19, 2002
    Assignee: Dynal AS
    Inventors: Joakim Lundeberg, Mathias Uhlen
  • Patent number: 6267964
    Abstract: A process for extending the half-life in vivo by a biologically active protein or peptide, characterized by covalently coupling said protein or peptide to a polypeptide fragment capable of binding to a serum protein, whereby when administering the resulting protein or peptide conjugate its binding to the serum protein results in extended biological activity, the use of the protein or peptide conjugate above for manufacturing a medicament which, when administered to a mammal including man, shows extended half-life in vivo; and a method of therapeutic or prophylactic treatment.
    Type: Grant
    Filed: December 8, 1993
    Date of Patent: July 31, 2001
    Assignee: Affibody Technology Sweden AB
    Inventors: Per Åke Nygren, Hans Wigzell, Mathias Uhlén
  • Patent number: 6210891
    Abstract: The present invention provides a method of identifying a base at a target position in a single-stranded sample DNA sequence wherein an extension primer, which hybridizes to the sample DNA immediately adjacent to the target position, is provided and the sample DNA and extension primer are subjected to a polymerization reaction in the presence of a deoxynucleotide or dideoxynucleotide, whereby the deoxynucleotide or dideoxynucleotide will only become incorporated and release pyrophosphate if it is complementary to the base in the target position. Release of pyrophosphate is detected enzymatically and pyrophosphate detection enzyme(s) are included in the polymerization step.
    Type: Grant
    Filed: July 6, 1999
    Date of Patent: April 3, 2001
    Assignee: Pyrosequencing AB
    Inventors: Pål Nyren, Mathias Uhlen, Mostafa Ronaghi
  • Patent number: 6149911
    Abstract: The present invention relates to a process for improving the immunogenicity of an immunogen, an antigen or a hapten, when it is administered to a host, independently of the mode of administration, characterized in that the said antigen or hapten is coupled covalently to a support molecule in order to form a complex, and in that this support molecule is a polypeptide fragment which is able to bind specifically to mammalian serum albumin. The invention also relates to the use, as a medicament, of the product which can be obtained in this way.
    Type: Grant
    Filed: July 1, 1997
    Date of Patent: November 21, 2000
    Assignee: Pierre Fabre Medicament
    Inventors: Hans Binz, Thien Nguyen Ngoc, Christine Andreoni, Per Ake Nygren, Stefan Stahl, Mathias Uhlen
  • Patent number: 6130091
    Abstract: A method for obtaining a Staphylococcus carnosus bacterium expressing at its membrane surface a recombinant polypeptide derived from RSV protein G, said polypeptide having a sequence which is a modification of SEQ ID No. 1 and SEQ ID No. 2 (sequence encompassed between residues 130 and 230 of RSV A and RSV B protein G respectively) wherein at least one of position 44 and 57 is serine is disclosed.
    Type: Grant
    Filed: July 1, 1997
    Date of Patent: October 10, 2000
    Inventors: Hans Binz, Thien Nguyen Ngoc, Stefan Stahl, Mathias Uhlen, Per Ake Nygren
  • Patent number: 5958736
    Abstract: Tripartite recombinant DNA encoding fusion proteins which comprise three sequences, i.e., a signal peptide which is operable in a Gram positive bacterium, an immunogenic polypeptide linked thereto which is not normally expressed in a Gram positive bacterium, and a cell wall spanning and a membrane anchoring sequence, as well as their use in Gram positive bacteria to express the resultant fusion protein on their surface are described. The preferred cell wall spanning and anchoring polypeptides include Staphylococcus protein A and Streptococcus protein G.
    Type: Grant
    Filed: April 8, 1996
    Date of Patent: September 28, 1999
    Assignee: Pierre Fabre Medicament
    Inventors: Stefan St.ang.hl, Per-.ANG.ke Nygren, Marianne Hansson, Mathias Uhlen, Thien Ngoc Nguyen